Isabel Álvarez

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 909 citations

Medicine, Endocrinology, Oncology +4

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert et al. · BMC Medical Genomics · 2012 · 343 citations · Full text

Medicine, Cancer Biology, Oncology +17

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacology +17

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15